J B Chemicals Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: J B Chemicals Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $2.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

J B Chemicals Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $2.4M Trade | TransData Nexus

J B Chemicals Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $2.4M Total Trade · DGFT Verified

J B Chemicals Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $2.4M across 5 products in 4 therapeutic categories. Based on 115 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Nifedipine ($1.1M), Atenolol ($834.6K), Mebendazole ($313.9K).

J B Chemicals Pharmaceuticals Limited — Export Portfolio & Destination Treemap

J B Chemicals Pharmaceuticals Limited pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is J B Chemicals Pharmaceuticals Limited? — Company Overview & Market Position

J. B. Chemicals & Pharmaceuticals Limited (JBCPL) was established on December 18, 1976, in Mumbai, Maharashtra, India. The company specializes in the manufacturing and marketing of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs). Its diverse product portfolio spans various therapeutic areas, including cardiovascular, antimalarial, antiparasitic, and central nervous system (CNS) disorders.

As of March 2026, JBCPL reported a revenue of ₹3,333.32 crore and a net worth of ₹2,886.26 crore. The company employs approximately 5,984 professionals across its operations. JBCPL is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 506943 and on the National Stock Exchange (NSE) under JBCHEPHARM. The company's Corporate Identification Number (CIN) is L24390MH1976PLC019380.

What Does J B Chemicals Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Nifedipine$1.1M 2Atenolol

Product Portfolio — Top 5 by Export Value

J B Chemicals Pharmaceuticals Limited exports 5 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Nifedipine	Cardiovascular	$1.1M	35	3.6%	6
2	Atenolol	Cardiovascular	$834.6K	31	2.1%	12
3	Mebendazole	Antimalarial & Antiparasitic	$313.9K	40	2.3%	7
4	Lorazepam	CNS & Psychiatric	$133.9K	5	5.3%	6
5	Nicotine	Other	$24.6K	4	0.2%	9

J B Chemicals Pharmaceuticals Limited exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $2.4M. The top category is Cardiovascular (80.3% of portfolio), followed by Antimalarial & Antiparasitic (13.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

J B Chemicals Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

JBCPL operates multiple state-of-the-art manufacturing facilities across India, including locations in Thane, Belapur, Ankleshwar, Panoli, and Daman. These facilities are equipped to produce a wide range of pharmaceutical formulations, herbal remedies, and APIs, ensuring compliance with global quality standards. The company's manufacturing units are certified by prominent global regulators, reflecting its commitment to quality and compliance.

3Key Leadership

As of March 2026, the key leadership at JBCPL includes:

Nikhil Ashokkumar Chopra: Chief Executive Officer (CEO) and Whole-Time Director.

Sumit Bose: Non-Executive & Independent Director.

Gaurav Trehan: Non-Executive Director.

Richa Arora: Non-Executive Independent Director.

Ashwani Kumar Puri: Non-Executive Independent Director.

Prashant Kumar: Non-Executive Director.

Akshay Tanna: Non-Executive & Non-Independent Director.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does J B Chemicals Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

JBCPL has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its pharmaceutical formulations from regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. These approvals facilitate the company's market access and distribution in these regions. JBCPL's commitment to quality and compliance is further demonstrated by its adherence to Good Manufacturing Practices (GMP) and other regulatory standards.

2Emerging Markets

JBCPL has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in over 40 countries, reflecting its global reach and commitment to providing quality healthcare solutions. JBCPL's adherence to World Health Organization (WHO) prequalification standards has enabled it to access and supply medicines in these regions, ensuring the availability of essential pharmaceuticals to diverse populations.

3Geographic Strategy

J B Chemicals Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

JBCPL has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), enabling the company to market its pharmaceutical formulations in the United States. The company has received approvals for its Abbreviated New Drug Applications (ANDAs) and has filed Drug Master Files (DMFs) for its active pharmaceutical ingredients (APIs). JBCPL's facilities have undergone FDA inspections, and the company maintains a history of compliance with FDA regulations, reflecting its commitment to quality and regulatory adherence.

2WHO & EU GMP

JBCPL's manufacturing facilities are certified by the World Health Organization (WHO) and the European Union (EU) Good Manufacturing Practices (GMP) standards. These certifications affirm the company's adherence to international quality standards, ensuring the safety and efficacy of its pharmaceutical products. The company's commitment to maintaining WHO and EU GMP certifications underscores its dedication to delivering high-quality medicines to global markets.

3CDSCO & Indian Regulatory

J B Chemicals Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

JBCPL operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. Its product portfolio, including formulations such as nifedipine, atenolol, mebendazole, lorazepam, and nicotine, positions it in therapeutic categories like cardiovascular, antimalarial, antiparasitic, and CNS disorders. The company's market share in these categories reflects its competitive standing. JBCPL's focus on quality, regulatory compliance, and strategic market expansion contributes to its competitive edge in the industry.

2Key Differentiators

JBCPL's key differentiators include its diverse product portfolio across multiple therapeutic areas, strong presence in both regulated and emerging markets, and commitment to quality and regulatory compliance. The company's state-of-the-art manufacturing facilities, certified by global regulators, ensure the production of high-quality pharmaceutical formulations. JBCPL's strategic focus on expanding its product offerings and enhancing its global footprint positions it as a competitive player in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating J B Chemicals Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

JBCPL has a strong track record in the pharmaceutical industry, with consistent export volumes and a diverse product portfolio. The company's adherence to international quality standards and regulatory requirements enhances its reliability as a supplier. JBCPL's commitment to ethical practices, patient-centric approaches, and on-time delivery further underscores its dependability in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications when considering JBCPL as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practices.

EU GMP Certification

Frequently Asked Questions — J B Chemicals Pharmaceuticals Limited

How many pharmaceutical products does J B Chemicals Pharmaceuticals Limited export from India?

J B Chemicals Pharmaceuticals Limited exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Nifedipine ($1.1M), Atenolol ($834.6K), Mebendazole ($313.9K), Lorazepam ($133.9K), Nicotine ($24.6K). Total export value is $2.4M.

What is J B Chemicals Pharmaceuticals Limited's total pharmaceutical export value?

J B Chemicals Pharmaceuticals Limited's total pharmaceutical export value is $2.4M, based on 115 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does J B Chemicals Pharmaceuticals Limited cover?

J B Chemicals Pharmaceuticals Limited exports across 4 therapeutic categories. The largest are Cardiovascular (80.3%, 2 products), Antimalarial & Antiparasitic (13.1%, 1 products), CNS & Psychiatric (5.6%, 1 products).

Get Full J B Chemicals Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.